SHP2 deregulation was shown to be involved in insulin resistance in type 2 diabetes mellitus (T2DM); accordingly, SHP2 inhibition or liver-specific PTPN11 deletion delayed IR endocytosis, enhanced insulin-activated AKT pathway and improved insulin sensitivity in mice [51]. This evidence concerns the gene AKT1 and type 2 diabetes mellitus.